capsaicin palmitate | 1002331-03-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚酯
• 英文名称: capsaicin palmitate
• 英文别名: palmitoyl ester of capsaicin；capsaicin palmitoyl ester；[2-methoxy-4-[[[(E)-8-methylnon-6-enoyl]amino]methyl]phenyl] hexadecanoate
• CAS: 1002331-03-4
• 化学式: C₃₄H₅₇NO₄
• 分子量: 543.831
• InChiKey: IJEHGTSZGMRMKC-ZBJSNUHESA-N

物化性质

• 沸点：
  653.9±55.0 °C(Predicted)
• 密度：
  0.965±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  11
• 重原子数：
  39
• 可旋转键数：
  25
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  64.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  辣椒碱 、 棕榈酰氯 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 以95%的产率得到capsaicin palmitate
  参考文献：
  名称：

  Pharmaceutical Compositions Comprising Capsaicin Esters for Treating Pain and Cold Sores

  摘要：

  本发明涉及含有辣椒素酯及至少一种来自水杨酸酯、薄荷脑、乳香酸、二甲基亚砜、甲基亚砜、非甾体抗炎药、皮质类固醇、鸸鹋油、阿片受体激动剂和拮抗剂、NMDA受体拮抗剂、曲马多、透明质酸、α2δ受体配体、檀香醇、檀香醋酸酯、白檀醇、白檀醋酸酯、芦荟凝胶和芦荟汁的药物组合物，用于改善治疗特性。此外，本发明涉及含有高浓度辣椒素酯的药物组合物。此外，本发明涉及通过给予本发明的药物组合物来减轻受试者因各种疾病而导致的疼痛的方法。此外，本发明涉及通过给予含有辣椒素酯及来自檀香醇、檀香醋酸酯、白檀醇和白檀醋酸酯中的一种的药物组合物来减轻受试者因感冒引起的发热疱疹的方法。

  公开号：

  US20140134261A1

文献信息

• Novel pharmaceutical compositions for treating chronic pain and pain associated with neuropathy
  申请人：Singh Ulagaraj Chandra

  公开号：US20080058362A1

  公开（公告）日：2008-03-06

  Chronic pain is alleviated in a mammal suffering there from by administering to the mammal a chronic pain alleviating amount of a nontoxic N-methyl-D-aspartate receptor antagonist such as dextromethorphan, dextrorphan, ketamine or pharmaceutically acceptable salt thereof, in combination with a μ-opiate analgesic such as tramadol or an analogously acting molecular entity, and a capsaicin or an ester of capsaicin, and optionally in sustained release dosage form.

  通过向哺乳动物投予一定量的无毒N-甲基-D-天冬氨酸受体拮抗剂，如右美沙芬、右美沙芬酮、氯胺酮或其药用盐，结合μ-阿片类镇痛药，如曲马多或类似作用的分子实体，以及辣椒素或辣椒素酯，可缓解患有慢性疼痛的哺乳动物的疼痛，也可以采用持续释放剂量形式。
• Esters of capsaicinoids as dietary supplements
  申请人：Singh Chandra Ulagaraj

  公开号：US20100120912A1

  公开（公告）日：2010-05-13

  Provided are nutraceutical or dietary supplemental compositions comprising esterified capsaicinoids. The esterified capsaicinoids may converted to the active parent capsaicinoid compound following enzymatic or chemical hydrolysis. In various embodiments, these esterified capsaicinoids have a higher lipophilicity, lipid solubility and result in less irritation to the stomach than the parent capsaicinoid, and hence may be included in certain dietary supplement formulations, including capsules, pills and tablets dietary supplement formulations. The dietary supplement compositions may be used for pain management in mammals in vivo and/or in the treatment of various pathological conditions in humans.

  提供的是含酯化辣椒素的营养保健品或膳食补充剂组合物。酯化辣椒素可以在酶解或化学水解后转化为活性母辣椒素化合物。在各种实施方式中，这些酯化辣椒素具有较高的亲脂性、脂溶性，对胃部的刺激较小，因此可以包含在某些膳食补充剂配方中，包括胶囊、药丸和片剂膳食补充剂配方。这些膳食补充剂组合物可用于体内哺乳动物的疼痛管理和/或用于治疗人类的各种病理状况。
• Esters of capsaicin for treating pain
  申请人：Singh Chandra Ulagaraj

  公开号：US20080020996A1

  公开（公告）日：2008-01-24

  The present invention relates to the formulations of ester derivatives of capsaicin and ester derivatives of myristoleic acid. These derivatives are capable of reverting to the active parent compound following enzymatic or chemical hydrolysis. These derivatives have a higher lipophilicity, lipid solubility and less irritation to the skin than the parent compound, and hence are better able to be incorporated into certain pharmaceutical formulations, including cream and ointment pharmaceutical formulations. The pharmaceutical compositions of the present invention contain a compound of following formula (Ia): R—CO-CAP   (Ia) wherein CAP refers to collectively the capsaicins represented in FIG. 1 and a compound of formula (Ib): MCO-O—R   (Ib) wherein MCO refers to myristoleic acid. In formulae Ia and Ib, R is selected from alkyl groups of up to about 18 carbon atoms and aryl groups of up to about 18 carbon atoms and alkylene group of up to about 18 carbon atoms and an arylene group of up to about 18 carbon atoms. The alkyl, aryl and alkylene groups may be substituted or un-substituted, branched or straight chains. In addition, R may contain heteroatoms and may be straight chained or branched. The pharmaceutical compositions containing compounds of formulae Ia and Ib are useful for pain management in mammals in vivo and have been contemplated to be used in the treatment of various pains in humans.

  本发明涉及辣椒素酯衍生物和肉豆蔻油酸酯衍生物的配方。这些衍生物能够在酶解或化学水解后恢复为活性母化合物。这些衍生物具有更高的亲脂性、脂溶性，对皮肤的刺激性较小，因此更容易被纳入某些药物配方中，包括膏剂和药膏配方。本发明的药物组合物含有下式（Ia）的化合物：R—CO-CAP（Ia），其中CAP指的是在图1中表示的辣椒素，和下式（Ib）的化合物：MCO-O—R（Ib），其中MCO指的是肉豆蔻油酸。在式Ia和Ib中，R选自碳原子数最多约为18的烷基基团和碳原子数最多约为18的芳基基团以及碳原子数最多约为18的烷基基团和碳原子数最多约为18的芳基基团。烷基、芳基和烷基基团可以是取代或未取代的，支链或直链。此外，R可能含有杂原子，可能是直链或支链的。含有式Ia和Ib的药物组合物对于体内哺乳动物的疼痛管理是有用的，并已考虑用于治疗人类的各种疼痛。
• Novel Pharmaceutical Compositions for Treating Chronic Pain and Pain Associated with Neuropathy
  申请人：Singh Chandra U.

  公开号：US20130189354A1

  公开（公告）日：2013-07-25

  The present invention relates to compositions and methods for treating pain wherein the compositions comprise a combination of tramadol or a pharmaceutically acceptable salt thereof, magnesium or a pharmaceutically acceptable salt thereof; and gabapentin or pregabalin. The therapeutic combination can further contain capsaicin or an ester of capsaicin.

  本发明涉及用于治疗疼痛的组合物和方法，其中所述组合物包括曲马多或其药学上可接受的盐、镁或其药学上可接受的盐；以及加巴嘌醇或普瑞巴林。治疗组合物还可以包含辣椒素或辣椒素酯。
• PHARAMACEUTICAL COMPOSITIONS FOR TREATING CHRONIC PAIN AND PAIN ASSOCIATED WITH NEUROPATHY
  申请人：Singh Chandra Ulagaraj

  公开号：US20110039875A1

  公开（公告）日：2011-02-17

  The present invention provides methods and compositions for the treatment of neuropathic pain. In certain embodiments, compositions comprising an dextromethorphan (or other N-methyl-D-aspartate receptor antagonist), tramadol, and gabapentin can synergistically act to reduce pain in a human patient. Pharmaceutical compositions may also comprise a capsaicinoid, an esterified capsaicinoid, and/or a tricyclic antidepressant.

  本发明提供了治疗神经病痛的方法和组合物。在某些实施例中，含有右美沙芬（或其他N-甲基-D-天门冬氨酸受体拮抗剂）、曲马多和加巴喷丁的组合物可以协同作用于人类患者，以减轻疼痛。药物组合物也可以包括辣椒素类、酯化辣椒素类和/或三环抗抑郁剂。